Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
10.1186/s12933-016-0480-8 236
Obes Sci Pract 10(1):e706 Jensen AB et al (2023) Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study
Semaglutide is a subcutaneous injection, meaning it should reach the fatty layer 5 to 8 millimeters below the skin surface but never enter muscle tissue
[23] [24] This pattern reflects the chronic nature of obesity as a disease and suggests that therapy may need to be continued indefinitely for sustained weight management
Anything above that requires more than 1 mL, which a standard insulin syringe cannot hold
doi: 10.1021/acs.jafc.3c04526 192 BaiYMinRChenPMeiSDengFZhengZet al
